Skip to content

Treatment with Steamed iodine compounds to kill COVID in the lower respiratory system of patients with confirmed COVID pneumonia and result in a rapid improvement in important parameters of infection

Iocure Priyadarshani Nursing Home Trial Iodine Inhalation for Covid Pneumonia - Iocure3

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/11/037927
Enrollment
100
Registered
2021-11-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J06- Acute upper respiratory infections

Interventions

Intervention1: Povidone Iodine 10% Appropriate dilution of 10% Iodine solution at the patient�s bedside and delivered through a vaporizer or a simple cooking pot with the patient breathing de

Sponsors

Iocure Inc
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: --positive COVID test --lung involvement as determined by CT imaging --oxygen saturation 92-97% --Adults of 50 kg or greater --No pregnant or lactating women --No one with a history of iodine allergy (dyes, shellfish) --No history of thyroid disease --Fever above 98.6 degrees Fahrenheit --Only other current COVID treatment is supportive; exclusion if on hydroxychloroquine, OK if on paracetamol, but that should be recorded Group 4: As above, with saturation below 92%

Exclusion criteria

Exclusion criteria: Less than 50 kg Less than 21 years old Allergies to iodine and iodine-containing substances Allergies to shellfish History of thyroid disease Pregnancy Nursing mothers High blood potassium or chloride Heart block Taking hydroxychlolorquine Any major existing medical problem with multiple medications or problems, for example, more than mild congestive heart failure with use of several mediations. Simple hypertension is not per se sufficient for exclusion. Another example of exclusion would be uncontrolled diabetes.

Design outcomes

Primary

MeasureTime frame
temperature, oxygen saturation, respiratory rate, cardiac rateTimepoint: Day 1,2,3 and Day 7 post dose

Secondary

MeasureTime frame
Adverse events reported improvement in clotting times, PT, PTTTimepoint: Day 1,2,3 and Day 7 post dose

Countries

India

Contacts

Public ContactDr Hemant Gupta

Priyadarshani Nursing Home

drhemantgupta@hotmail.com9870456888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026